It doesn't take two: The Tipline for 18 June 2019

As the healthcare industry remains under scrutiny in the US, Pfizer has marched ahead with an $11 billion merger that could reshape the cancer treatment landscape. Meanwhile, a US senator is calling on Congress to reorganise civil antitrust enforcement so that it is done under one roof and not split between two authorities.

Unlock unlimited access to all Global Competition Review content